چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| علی ایمانی | سوم |
| مینا گلستانی | اول |
| عنوان | متن |
|---|---|
| خلاصه مقاله | OBJECTIVES: To evaluate the cost-effectiveness analysis of two Disease-modifying drugs (DMD) used as first-line treatment of Relapsing Remitting Multiple Sclerosis (RRMS): interferon IFN-1a IM injection (Avonex®) and IFN -1b SC injection (Betaferon ®) from Iranian Ministry of Health perspective. METHODS: A cost-effectiveness analysis (CEA) was performed from Ministry of Health (MoH). The outcome of interest was number of relapses avoided. Costs were reported in 2011 USD. Costs and outcomes were discounted at 5%. The time horizon was two years. All uncertainties were tested via one-way sensitivity analyses. RESULTS: Total costs per patient over the time horizon of a study were estimated at 39923, 47670 and 52045 USD for symptom management, IM IFN-1a and SC IFN-1b, respectively. The incremental cost per relapse avoided was 25823 and 14965 USD for IM IFN-1a and SC IFN-1b, respectively, compared with no active treatment (symptom management). Results were sensitive to the discount rate, frequency of relapse and cost of DMDs. CONCLUSIONS: The cost-effectiveness analysis determined that INF-1b SC (Betaferon® ) was the best strategy of the two immunomodulatory therapies used to treatment of patients experiencing an relapsing-remitting multiple sclerosis (RRMS) and resulted in better outcomes than symptom management alone. Sensitivity analyses indicated that the model was sensitive to changes in a number of key parameters, and thus changes in these |
| کلمات کلیدی | Economic Evaluation, RRMS, Iran |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| PND10.pdf | 1395/08/12 | 56319 | دانلود |
| PND10.pdf | 1395/08/12 | 56319 | دانلود |
